Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,41%
1 076,13
-15,38
-1,41%
—1 091,511 090,401 090,401 073,69——
SIXC
Communications
SIXC
Communications
SIXC
-0,55%
606,74
-3,37
-0,55%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,88%
1 248,82
+10,84
+0,88%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,17%
1 724,36
-20,35
-1,17%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,72%
635,59
-4,59
-0,72%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-0,76%
843,15
-6,43
-0,76%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,55%
216,29
-1,19
-0,55%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,08%
3 263,41
+2,72
+0,08%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,34%
939,24
-3,21
-0,34%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,29%
1 462,56
-4,24
-0,29%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,71%
2 380,40
-17,10
-0,71%
—2 397,502 395,032 412,012 370,64——
Q1 2026 earnings • released • EPS miss -16,86% • Revenue beat +1,93%
See results
BMRN:NASDAQ
Biomarin Pharmaceutical Inc
55,46 $
+2,59%
(+1,40) 1D
54,87 $
-1,06% (-0,59)
After hours
Closed: 4 մյս, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMRN...
Open
53,66 $
High
55,53 $
Low
53,45 $
Mkt. cap
10,72 մլրդ
Avg. vol.
1,65 մլն
Volume
0,00
P/E ratio
30,73
52-wk high
66,28 $
52-wk low
50,76 $
EPS
1,80 $
Beta
0,23
Shares outstanding
192,32 մլն
No. of employees
3 հզր
News stories
From sources across the web
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3,22 հզր
Foundedմրտ 1997
HeadquartersՍան Ռաֆայել, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitebiomarin.com
Last report
04 մյս, 2026 թ.
Fiscal Period
Q1 2026
Normalized EPS / Estimate
0,76/ (0,91 est.)USD
-16,86%miss
Revenue / Estimate
766,21 մլն/ (751,68 մլն est.)USD
+1,93%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. մրտ
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
Revenue
745,14 մլն
825,41 մլն
776,13 մլն
874,56 մլն
Cost of goods sold
310,29 մլն
311,40 մլն
549,56 մլն
348,91 մլն
Cost of revenue
310,29 մլն
311,40 մլն
549,56 մլն
348,91 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
206,12 մլն
232,28 մլն
268,42 մլն
324,16 մլն
Operating expense
210,96 մլն
237,12 մլն
273,26 մլն
329,01 մլն
Total operating expenses
521,25 մլն
548,52 մլն
822,82 մլն
677,92 մլն
Operating income
223,89 մլն
276,89 մլն
-46,69 մլն
196,64 մլն
Other non operating income
-1,95 մլն
4,83 մլն
5,09 մլն
1,02 մլն
EBT including unusual items
238,09 մլն
297,87 մլն
-26,32 մլն
-27,15 մլն
EBT excluding unusual items
238,09 մլն
297,87 մլն
-26,32 մլն
214,10 մլն
Income tax expense
52,40 մլն
57,34 մլն
4,42 մլն
19,42 մլն
Effective tax rate
22,01%
19,25%
-16,79%
-71,52%
Other operating expenses
-
-
-
-
Net income
185,69 մլն
240,53 մլն
-30,74 մլն
-46,57 մլն
Net profit margin
24,92%
29,14%
-3,96%
-5,33%
Earnings per share
1,13
1,44
0,12
0,46
Interest and investment income
19,01 մլն
18,83 մլն
17,85 մլն
19,21 մլն
Interest expense
-2,86 մլն
-2,68 մլն
-2,58 մլն
-2,78 մլն
Net interest expenses
16,15 մլն
16,15 մլն
15,28 մլն
16,43 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
245,96 մլն
295,45 մլն
-28,20 մլն
209,68 մլն
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer